Literature DB >> 10605410

Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.

J Scurry1, M A Duggan.   

Abstract

The separation of mesothelial hyperplasia from early malignant mesothelioma remains one of the most difficult problems in histopathology. Inconclusive cases are termed "atypical mesothelial hyperplasia" and treated expectantly. A 49 year old male pipeline engineer was diagnosed as having atypical mesothelial hyperplasia in appendiceal serosa by the US-Canadian Mesothelioma Panel. Eight years later, he developed overtly malignant peritoneal and pleural mesothelioma. In hindsight, histological similarities between the diffuse malignant mesothelioma and the atypical mesothelial proliferation suggested malignancy from the outset. The most important of these features were the degree of mesothelial proliferation, micronodularity, architectural complexity, superficial invasion, uniform mild cytological atypia, and the absence of a clinical cause for a benign mesothelial proliferation. Ancillary investigations including immunohistochemistry were of no benefit in determining whether the atypical mesothelial hyperplasia was benign or malignant. Careful histological examination remains the mainstay of the diagnosis of early mesothelioma.

Entities:  

Mesh:

Year:  1999        PMID: 10605410      PMCID: PMC501499          DOI: 10.1136/jcp.52.7.535

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

Review 1.  Differentiation of serosal hyperplasia and neoplasia in biopsies.

Authors:  W T McCaughey; M Al-Jabi
Journal:  Pathol Annu       Date:  1986

Review 2.  Pathology of malignant mesothelioma.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  1997-05       Impact factor: 5.087

3.  p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.

Authors:  P T Cagle; R W Brown; R M Lebovitz
Journal:  Hum Pathol       Date:  1994-05       Impact factor: 3.466

4.  p53 expression is common in malignant mesothelioma.

Authors:  G Kafiri; D M Thomas; N A Shepherd; T Krausz; D P Lane; P A Hall
Journal:  Histopathology       Date:  1992-10       Impact factor: 5.087

5.  p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.

Authors:  F G Mayall; H Goddard; A R Gibbs
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

6.  Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.

Authors:  M Ramael; G Lemmens; C Eerdekens; C Buysse; I Deblier; W Jacobs; E van Marck
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

Review 7.  Latent period for malignant mesothelioma of occupational origin.

Authors:  B P Lanphear; C R Buncher
Journal:  J Occup Med       Date:  1992-07

8.  Flow cytometric analysis of malignant pleural mesotheliomas.

Authors:  G C Burmer; P S Rabinovitch; B G Kulander; V Rusch; M A McNutt
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

  8 in total
  3 in total

1.  A rare cause of heart failure with preserved ejection fraction: primary pericardial mesothelioma masquerading as pericardial constriction.

Authors:  Russell Fernandes; Shravan Nosib; Dorothy Thomson; Nick Baniak
Journal:  BMJ Case Rep       Date:  2014-03-20

Review 2.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

3.  p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.

Authors:  So-My Koo; Soo-Taek Uh; Dong Won Kim; Ki-Up Kim; Yang-Ki Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.